脏参与慢性移植对宿主疾病
Nihar Desai1,2, Arjun Datt Law1,2, Christianne Bourlon3
1Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
European journal of haematology
|August 14, 2025
概括
移植与宿主疾病 (GvHD) 可以影响脏,在0.8%的移植患者中引起脏综合征. 及时的免疫抑制和活检对于管理这种并发症至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 移植与宿主疾病 (GvHD) 是异性造血干细胞移植 (HSCT) 后的一个常见并发症.
- 虽然典型的GvHD的目标是皮肤,眼睛,口腔和肝脏,但脏的参与越来越被认可,但特征不佳.
- 关于GvHD相关的病的数据有限,通常来自小型回顾性研究.
研究的目的:
- 调查HSCT接受者的脏参与的临床特征,诊断和结果.
- 为了确定与GvHD诱导的性综合征相关的特定病理.
- 评估免疫抑制疗法在治疗性GvHD时的疗效.
主要方法:
- 对1441名HSCT患者的回顾性分析.
- 识别患有性综合征的患者和活检确认膜性病 (MN).
- 临床数据的审查,包括蛋白尿,诊断的时间,静脉血栓,病理和治疗反应.
主要成果:
- 十二名患者 (0.8%) 患有性综合征,在HSCT后经过活检证明了MN,以前没有病.
- 中位蛋白尿是6.6g/24h;诊断发生在HSCT后1.8年和GvHD诊断后407天.
- 在12名患者中,11名患者的免疫抑制疗法导致了完全或部分反应;没有人患有不可逆转的功能障碍.
结论:
- 脏干扰,呈现为带有膜性病的性综合征,是HSCT的罕见但显著的并发症.
- 在没有特定生物标志物的情况下,脏活检对于诊断GvHD诱导的脏疾病至关重要.
- 早期的免疫抑制治疗对治疗脏GvHD和预防不可逆转的损伤是有效的.
相关概念视频
01:40Cell-mediated Immune Responses
72.5K
Overview
72.5K
01:24Tissue Transplantation
519
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
519
01:29Acute Kidney Injury III: Clinical Manifestations
94
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
94
01:26Kidney Transplant II: Surgical Procedure
75
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
75
01:16Kidney Transplant III: Nursing Management
81
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
81
01:22Bone Marrow Sampling and Transplants
495
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
495